Novel 4'-ethyl-5'-norcarbocyclic adenosine phosphonic acid analogues were synthesized from propionaldehyde 5 through a de novo acyclic synthetic route using reiterative Grignard additions and ring-closing metathesis (RCM) as key reactions. The synthesized nucleoside phosphonic acids analogues 17, 18, 19, and 21 were subjected to antiviral screening against human immunodeficiency virus.
Introduction
4'-Branched nucleosides were first investigated by Maag et al. 1 in 1992, and 4'-azido-thymidine (1) exerts potent activity against HIV-1. Extensive structure-activity studies found that other 4'-position lipophilic substituents, such as 4'-ethylthymidine (2), 2 also exhibited high antiviral activity against HIV. Molecular modeling studies demonstrated the presence of a narrow, relatively hydrophobic 4'-pocket that can accommodate these substitutions, contributing to enhanced potency. 3 5'-Nornucleoside phosphonic acid analogues such as d4AP (3) 4 may be potential anti-HIV agents and have encouraged the search for novel nucleosides in this class of compounds. 5 The spatial location of the oxygen atom, namely the β-position from the phosphorus atom in the nucleoside analogue, plays a critical role for antiviral activity by increasing binding capacity of the phosphonate analogues to target enzymes. 6 The phosphonate has certain advantages over its phosphate counterpart as it is metabolically stable because its phosphorus-carbon bond is not susceptible to hydrolytic cleavage. 7 Moreover, a phosphonate nucleoside analogue can skip the requisite first phosphorylation, a rate-limiting crucial step for the activation of nucleosides that ultimately leads to triphosphates. 8 Carbocyclic nucleosides are a group of compounds structurally similar to natural nucleosides in which the furanose oxygen is replaced by a methylene group. Replacement of the furanose ring oxygen by carbon is of particular interest because the resulting carbocyclic nucleosides possess greater metabolic stability to phosphorylase, 9 which cleaves the glycosidic bond of nucleosides. The recent discovery of 4'-ethynyl-cpAP (4) 3 as an anti-HIV agent gave strong impetus to the search for novel nucleosides in this class of compounds.
Stimulated by these findings that 4'-branched nucleoside analogues and 5'-nornucleoside phosphate had excellent biological activities, we sought to synthesize a novel class of nucleosides comprising 4'-ethyl branched carbocyclic-5'-norcarbocyclic phosphonic acid analogues to search for more efficient therapeutic agents against HIV and to provide analogues used in probing the conformational preferences of enzymes associated with the metabolism of nucleosides and nucleotides.
Results and Discussions
As depicted in Scheme 1, the target compounds were prepared from protected propionaldehyde 5. 10 The aldehyde functional group of 5 was subjected to a carbonyl addition reaction by ethylmagnesium bromide to furnish the secondary alcohol 6, which was subjected to oxidation using pyridium chlorochromate (PCC) to provide ketone derivative 7. The corresponding ketone functional group of 7 was again subjected to an addition reaction by vinylmagnesium bromide to give the tertiary hydroxyl analogue (±)-8, which was successfully protected using p-methoxybenzyl chloride (PMBCl) to give the fully protected compound (±)-9. Removal of the silyl protecting group of (±)-9 using t-butylammonium fluoride (TBAF) provided the primary alcohol (±)-10, which was oxidized to the aldehyde (±)-11 using Swern oxidation conditions (DMSO, oxalyl chloride, TEA). The aldehyde (±)-11 was subjected to nucleophilic Grignard conditions with vinylmagnesium bromide to give divinyl (±)-12, which was subjected to ring-closing metathesis (RCM) conditions using a 2nd generation Grubbs catalyst 11 to provide ethyl- 
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Scheme 3. Synthesis of desired 5'-norcarbocyclic adenosine phosphonic acid analogues ated cyclopentenol 13a (39%) and 13b (40%), which were readily separated by silica gel column chromatography. The NOE experiments with cyclpopentenols 13a and 13b confirmed these assignments. As expected, NOE enhancements were found between the cis-oriented hydrogens. Upon irradiation of C1-H, weak NOE patterns were observed at the proximal hydrogens of compound 13b [C 4 -CH 2 (0.24%)] versus those of compound 13a [C4-CH2 (0.82%)] (Figure 2) .
To synthesize the desired 5'-norcarbocyclic adenine nucleoside analogue, the protected cyclopentenol 13b was treated with 6-chloropurine under Mitsunobu conditions (DIAD and PPh3). Slow addition of diisopropyl azodicarboxylate (DIAD) to a mixture of cyclopentenol 13b, triphenylphosphine, and the 6-chloropurine in anhydrous tetrahydrofuran gave a yellow solution that was stirred for 3 h at -20 o C to give a protected 6-chloropurine analogue 14 (Scheme 2). 12 The PMB protection group was removed with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) 13 to the 5'-nornucleoside analogue 15, which was treated with diethylphosphonomethyl triflate 14 using lithium t-butoxide to yield the nucleoside phosphonate 16. The chlorine group of 16 was then converted to amine with methanolic ammonia at 70 o C to give a corresponding adenine phosphonate derivative 17.
The nucleoside phosphonate mimics the overall shape and geometry of a nucleoside monophosphate. Hydrolysis of 17 by treatment with bromotrimethylsilane in CH 3 CN in the presence of 2,6-lutidine gave an adenine phosphonic acid derivative 18. 15 
Bishydroxylation
16 of the double bond in 17 was accomplished with a catalytic amount of osmium tetraoxide (OsO 4 ) and 4-methyl-morpholine N-oxide (NMO) as the oxidant to give the dihydroxylated isomer 19 (34%) and 20 (29%), with a relatively low stereoselectivity (Scheme 3). 17 Their stereochemistries were also readily determined by NOE experiments. These stereochemical outcomes suggest that the steric environments of α and β-faces on the cyclopentene ring might be equivalent. Hydrolysis of the diethyl phosphonate functional groups of 19 by a similar procedure described for 18 gave an adenine phosphonic acid derivative 21.
The synthesized nucleoside phosphonate and phosphonic acid analogues 17, 18, 19, and 21 were evaluated for antiviral activity against HIV-1. 18 As shown in Table 1 , nucleoside phosphonic acid 18 exhibited greater toxicity-dependent anti-HIV activity than its parent nucleoside phosphonate 17. However, nucleotide analogs 19 and 21 did not show anti-HIV activity nor cytotoxicity up to 100 μM.
In summary, on the basis of potent anti-HIV activity of 4'-alkyl branched nucleoside and 5'-norcarbocyclic nucleoside analogues, we have designed and successfully synthesized novel 4'-ethyl-5'-norcarbocyclic nucleotide analogues starting from propionaldehyde. In this series, adenosine phosphonic acid derivative 18 showed moderate toxicity-dependent anti-HIV-1 activity.
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. The elemental analyses were performed using a Perkin-Elmer 2400 analyzer (PerkinElmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were performed under an atmosphere of nitrogen unless specified. Dry dichloromethane, benzene and pyridine were obtained by distillation from CaH2. Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
(±)-1-(t-Butyldimethylsilanyloxy)-pentan-3-ol (6). To a solution of 5 (2.5 g, 13.27 mmol) in dry THF (25 mL) was slowly added ethylmagnesium bromide (15.9 mL, 1.0 M solution in THF) at -20 o C and stirred 5 h at 0 o C. Saturated NH4Cl solution (16 mL) was added to the mixture, which was slowly warmed to rt. The mixture was further diluted with water (80 mL) and extracted with EtOAc (2 × 80 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , filtered, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:6) to give 6 (2.58 g, 89%) as a colorless oil: 
1-(t-Butyldimethylsilanyloxy)-pentan-3-one (7).
To a solution of compound 6 (1.39 g, 6.4 mmol) in CH2Cl2 (50 mL), 4 Å molecular sieves (3.75 g) and PCC (3.45 g, 16.05 mmol) were added slowly at 0 o C, and stirred overnight at room temperature. To the mixture, excess diethyl ether (400 mL) was then added. The mixture was stirred vigorously for 3 h at the same temperature, and the resulting solid was filtered through a short silica gel column. The filtrate was concentrated under vacuum and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give compound 7 (1.08 g, 78%) as a colorless oil: 
3-Ethyl-3-(4-methoxybenzyloxy)-pent-4-enal (11).
To a stirred solution of oxalyl chloride (212 mg, 1.67 mmol) in CH2Cl2 (10 mL) was added a solution of DMSO (195 mg, 2.5 mmol) in CH 2 Cl 2 (5.0 mL) dropwise at -78 o C. The resulting solution was stirred at -78 o C for 10 min, and a solution of alcohol 10 (210 mg, 0.839 mmol) in CH2Cl2 (10 mL) was added dropwise. The mixture was stirred at -78 o C for 30 min and TEA (507 mg, 5.01 mmol) was added. The resulting mixture was warmed to 0 o C and stirred for 30 min. H2O (15 mL) was added, and the solution was stirred at room temperature for 30 min. The mixture was diluted with water (120 mL) and then extracted with EtOAc (2 × 120 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO4, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:15) to give aldehyde compound 11 (189 mg, 91%) as a colorless oil: (
rel)-(1S,4S)-4-Ethyl-4-(4-methoxybenzyloxy)-cyclopent-2-enol (13a) and (rel)-(1R,4S)-4-ethyl-4-(4-methoxybenzyloxy)-cyclopent-2-enol (13b).
To a solution of 12 (205 mg, 0.74 mmol) in dry methylene chloride (6 mL) was added 2nd generation Grubbs catalyst (38.0 mg 0.0452 mmol). The reaction mixture was refluxed overnight and cooled to room temperature. The mixture was concentrated in vacuo, and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:12) to give cyclopentenol 13a (71.6 mg, 39%) and 13b (73.5 mg, 40%). Data for 13a: 
